This inventor holds 1 USPTO granted patent. Top assignee: Locus Genex Oy. Active years: 1995.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1995
Title: Raili Paasivuo: Innovator in Reactive Condition Diagnosis
Introduction
Raili Paasivuo is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of medical diagnostics, particularly in the detection of reactive conditions such as malignant tumors. His innovative approach has the potential to enhance early diagnosis and treatment options for patients.
Latest Patents
Raili Paasivuo holds a patent for a method that focuses on the diagnosis of reactive conditions. The invention involves determining the amount of cellular fibronectin in a body fluid, where an elevated amount serves as a marker for a reactive condition. This method is especially effective for diagnosing carcinomas, including colon carcinoma. He has 1 patent to his name.
Career Highlights
Paasivuo is associated with Locus Genex Oy, a company that specializes in advanced diagnostic solutions. His work at the company reflects his commitment to improving healthcare through innovative technologies. His contributions have been instrumental in developing methods that can lead to better patient outcomes.
Collaborations
Raili Paasivuo collaborates with talented professionals in his field, including Paul Partanen and Sari Ylatupa. Their combined expertise fosters a productive environment for innovation and research.
Conclusion
Raili Paasivuo's work in the diagnosis of reactive conditions exemplifies the impact of innovation in healthcare. His patented method offers promising advancements in the early detection of malignant tumors, showcasing the importance of research and collaboration in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile